DUYGU YILMAZ USTA

Dr. DUYGU YILMAZ USTA

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2022 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
DUYGU YILMAZ USTADUYGU YILMAZ USTA
DUYGU YILMAZ USTA
BTBurcu Timur
Burcu Timur
ZTZeynep Teksin
Zeynep Teksin
This study aimed to develop and optimize a self-nanoemulsifying drug delivery system (SNEDDS) of bosentan (BOS) to solve its poor oral bioavailability due to low water solubility. A pseudo-ternary phase diagram was created based on the solubility and emulsification studies. The major components of the formulation were selected as glyceryl monolinoleate (lipid), polyoxyl 40 hydrogenated castor oil (surfactant), and caprylocaproyl polyoxyl-8 glycerides (co-surfactant). The composition of BOS-SNEDDS was optimized using the Box-Behnken design (BBD) and then was characterized for various physicochemical properties. The in vitro dissolution, in vitro lipolysis, and ex-vivo permeability studies were performed and compared to SNEDDS and reference tablets. The fasted and fed state bioavailability of BOS-loaded SNEDDS was evaluated in Wistar rats (n = 6) compared to the reference. The prepared SNEDDS were thermodynamically stable with a droplet size of 17.11 nm, a polydispersity index of 0.180, and an emulsification time of <1 min. The BOS-loaded SNEDDS showed 3.0, 7.97, 4.23, and 4.94-fold increases in the percentages of cumulative dissolution compared to reference tablets in FaSSIF, FeSSIF, FaSSIF-V2, and FeSSIF-V2, respectively. The permeation study showed that the SNEDDS increased the drug permeation by 3.36, 19.2, 16.4, and 16.6-fold in FaSSIF, FeSSIF, FaSSIF-V2, and FeSSIF-V2, respectively. The enhancement of in vitro dissolution, in vitro lipolysis, and ex-vivo permeability was found significant (p < 0.05). SNEDDS was increased the Cmax and AUC 1.67 and 2.12-fold and 5.15 and 1.84-fold in fasted and fed state compared to the reference, respectively. The in vitro-in vivo relationship has been successfully performed for SNEDDS. These results indicated that the SNEDDS formulation could be a promising delivery system that enhances the absorption and oral bioavailability of BOS.

31 May 2024 in AAPS PharmSciTech
Verified
Journal Article
Open access
PDF file
DUYGU YILMAZ USTADUYGU YILMAZ USTA
DUYGU YILMAZ USTA
ZTZeynep Teksin
Zeynep Teksin
FTFATMANUR TUGCU-DEMİRÖZ
FATMANUR TUGCU-DEMİRÖZ
In transdermal applications of nonsteroidal anti-inflammatory drugs, the rheological and mechanical properties of the dosage form affect the performance of the drug. The aim of this study to develop emulgel and nanostructured lipid carrier NLC-based gel formulations containing ibuprofen, evaluate their mechanical properties, bioadhesive value and ex-vivo rabbit skin permeability. All formulations showed non-Newtonian pseudoplastic behavior and their viscosity values are suitable for topical application. The particle size of the nanostructured lipid carrier system was found to be 468 ± 21 nm, and the encapsulation efficiency was 95.58 ± 0.41%. According to the index of viscosity, consistency, firmness, and cohesiveness values obtained as a result of the back extrusion study, E2 formulation was found to be more suitable for transdermal application. The firmness and work of shear values of the E2 formulation, which has the highest viscosity value, were also found to be the highest and it was chosen as the most suitable formulation in terms of the spreadability test. The work of bioadhesion values of NLC-based gel and IBU-loaded NLC-based gel were found as 0.226 ± 0.028 and 0.181 ± 0.006 mJ/cm2 respectively. The percentages of IBU that penetrated through rabbit skin from the Ibuactive-Cream and the E2 were 87.4 ± 2.11% and 93.4 ± 2.72% after 24 h, respectively. When the penetration of ibuprofen through the skin was evaluated, it was found that the E2 formulation increased penetration due to its lipid and nanoparticle structure. As a result of these findings, it can be said that the NLC-based gel formulation will increase the therapeutic efficacy and will be a good alternative transdermal formulation. Graphical Abstract

18 July 2017 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
SGSıla Gülbağ
Sıla Gülbağ
DUYGU YILMAZ USTADUYGU YILMAZ USTA
DUYGU YILMAZ USTA
HGHAZAL EZGİ GÜLTEKİN
HAZAL EZGİ GÜLTEKİN
AOAyşe N. Oktay
Ayşe N. Oktay
ÖDÖzden Demirtaş
Özden Demirtaş
NÇNevin Çelebi
Nevin Çelebi
Nowadays pharmaceutical industries and regulatory authorities suggest new approaches such as Quality by Design principles to reduce experiments of formulation studies, improve product quality, save cost and time. SeDeM Expert System is a predictive approach for the preformulation studies and it provides information about suitability of API for direct compression by evaluating 12 parameters. The system also allows selecting appropriate excipients by determining same parameters to improve compressibility of API. The objective of this study was to develop direct compressed memantine orally disintegrating tablets using SeDeM Expert System. Memantine was found to have poor flow and compressibility properties. Three different direct compressibility and super disintegrating agents (Ludiflash®, Ludipress® and Parteck®) were used to improve compressibility of memantine and according to SeDeM diagrams, Parteck® was selected for final formulation. Memantine direct compressed tablets showed proper friability, hardness and thickness. The disintegration time of the tables were found below 15 s which was suitable for ODTs. It was found that SeDeM Expert System was easy to use and application of this method provided to develop memantine direct compressed ODT formulation was successful.



15 November 2021 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
SOSeval Olgac
Seval Olgac
DUYGU YILMAZ USTADUYGU YILMAZ USTA
DUYGU YILMAZ USTA
Tuba IncecayirTuba Incecayir
Tuba Incecayir
Tablet splitting is a common practice in clinical settings to lower doses, facilitate swallowing or save costs. Splitting devices can be used when hand splitting is difficult or painful. However, data on the accuracy of tablet splitting are limited and it presents a number of patient or formulation-related problems. Thirty nebivolol IR tablets on the Turkish market were split by hand, a tablet cutter (Rabır®) or a knife, and tested for weight variation, loss of mass, disintegration, and friability. The accuracy of split tablets was in the range of 75.4–121, 82.4–115, and 86.9–115% when split by hand, the cutter, and knife, respectively. No significant difference in accuracy was determined between the left and right sides split by the cutter (p = 0.222). The differences were significant for hand and knife splittings (p < 0.005). The precision was 9.02, 7.87, and 6.11% (CV%) for hand, tablet cutter, and knife, respectively. Only hand splitting failed to comply with the subdivision test of European Pharmacopoeia. The split portions met USP standards for friability (<1%). Splitting decreased the disintegration time (4.5 vs. 2.2 min). Overall, the accuracy of the tablet cutter was more favorable than hand splitting and knife. The study demonstrated that the splitting technique may result in inaccurate dosing and significant drug fluctuations for nebivolol tablets.